AI
Discover the World’s Fastest Business Insights
Get real-time alerts on funding rounds, executive hires, acquisitions, and more— plus verified contact details and AI-powered outreach to connect faster.
Sign up now to unlock exclusive data and opportunities.
Cardiff Oncology Secures $13.5 Million Equity Investment from Biotech-Focused Fundamental Institutional Investors Acorn Bioventures and CAM Capital
Cardiff Oncology Secures $13.5 Million Equity Investment from Biotech-Focused Fundamental Institutional Investors Acorn Bioventures and CAM Capital
06/16/20, 12:39 PM
Location
san diego
Money raised
$13 million
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia, today announced it has entered into a securities purchase agreement, jointly led by biotech-focused fundamental institutional investors, Acorn Bioventures and CAM Capital, at the closing price as of June 15, 2020. The financing includes common stock, non-voting Series E preferred stock and warrants for aggregate gross proceeds of $13.5 million. The proceeds will be used to accelerate the development of onvansertib and associated capital expenditures.
Company Info
Company
Acorn Bioventures
Location
san diego, california, united states
Additional Info
Acorn Bioventures invests across stages in small-cap public and private biotechnology companies focused on bringing novel innovative medicines to patients. Their investment flexibility allows them to provide value across the entire spectrum from seed financings, cross-over financings, IPOs, registered direct offerings, PIPEs, open market purchases, etc. Acorn Bio-ventures' investment process is based on fundamental research. They look for paradigm changing medical therapies, undiscovered or underappreciated assets, backed by outstanding teams.
Never Miss an Opportunity: Your #1 Sales Intelligence Tool
Get lightning-fast updates on funding rounds, executive hires, contract awards, and more—powered by AI-driven insights to help you connect with the right prospects first.